A Phase II Combined Modality Protocol of Debulking Surgery With Heated Intraoperative Chemotherapy (HIPEC) Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancers
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Adverse Event Rate and/or Laboratory Changes
研究概览
简要总结
The primary objective of this study is to investigate the feasibility, tolerability and safety of surgical debulking and resection with heated intraoperative chemotherapy (HIPEC) followed by repeated intraperitoneal chemotherapy for treatment of recurrent ovarian, primary peritoneal, and fallopian tube carcinomas.
详细描述
This is a phase II , open label, single center study of surgery followed by heated intraoperative cisplatin in patients with recurrent ovarian, primary peritoneal or fallopian tube cancers. Approximately twenty patients will receive surgery and intraoperative (hyperthermic) cisplatin followed by four consecutive courses of outpatient intraperitoneal cisplatin and doxorubicin given on days 1 and 8 during a 3 week cycle.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically confirmed ovarian, primary peritoneal or fallopian tube carcinoma.
- •Patients must have measurable evidence of recurrent intraabdominal disease based on Computed tomography (CT scan) findings.
- •Patients must fulfill the following with regard to prior chemotherapy:
- •4 weeks or greater since conclusion of prior chemotherapy;
- •Prior intraperitoneal chemotherapy with cisplatin is acceptable; and,
- •Prior systemic chemotherapy is acceptable.
- •Patients must have a Karnofsky Performance Status of > 70%
- •Patients must have an estimated life expectancy of at least 16 weeks.
- •Patient assurance of study compliance and geographic proximity that allows for adequate follow-up.
- •Patients must have adequate organ function at the screening visit as defined by the following laboratory values:
- •Absolute neutrophil count (ANC) ≥1.5 x 109/L Platelet count ≥100 x 109/L Hemoglobin ≥8 g/dL Albumin ≥ 2 g/dL Total Bilirubin ≤ 2.5 x ULN* Alkaline phosphatase ≤ 3.0 x ULN* Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x ULN Creatinine ≤ 1.5 x ULN
- •Patient must have signed informed consent
- •Patient must be at least 18 years of age
- •Following cytoreductive surgery, patient's residual disease should be no larger than 1cm to Receive HIPEC and continue with normothermic IP chemotherapy
- •Exclusion criteria:
- •Have active peripheral neuropathy of Grade 2 or greater intensity, as defined by the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE; Version 4).
- •Have experienced myocardial infarction within 6 months prior to enrollment or have New York Hospital Association (NYHA) Class III or IV heart failure (see section 16.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
- •Prior radiation therapy within 4 weeks of enrollment.
- •Have uncontrolled active systemic infection requiring therapy.
- •Have a history of allergic reaction attributable to compounds containing boron or mannitol or hypersensitivity reactions to drugs formulated with polysorbate
- •Have had a serious concomitant systemic disorders (including oncologic emergencies) incompatible with the study (at the discretion of the investigator).
- •Have had a "currently active" second malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix are not to be registered. Patients who are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse.
- •Have had any investigational agent within 4 weeks before enrollment into the study.
- •Have a history of a serious medical or psychiatric illness preventing informed consent or, in the opinion of the investigator, would make the patient a poor study candidate.
- •Evidence of extraabdominal metastasis on preinclusion thoracic computed tomography (CT) scans (i.e. brain or chest disease).
排除标准
- 未提供
研究组 & 干预措施
Out-Patient Intraperitoneal Chemotherapy
Intraoperative (hyperthermic) cisplatin followed by 4 courses of intraperitoneal cisplatin and doxorubicin given on days 1 & 8 during a 3 week cycle.
干预措施: Cisplatin (Drug)
Out-Patient Intraperitoneal Chemotherapy
Intraoperative (hyperthermic) cisplatin followed by 4 courses of intraperitoneal cisplatin and doxorubicin given on days 1 & 8 during a 3 week cycle.
干预措施: Doxorubicin (Drug)
结局指标
主要结局
Adverse Event Rate and/or Laboratory Changes
时间窗: 5 years
The adverse event rate and laboratory changes will be used to investigate the safety of surgical debulking with heated intraperitoneal chemotherapy (HIPEC) combined with repeated intraperitoneal chemotherapy.
Toxicity Rating Based on NCI Common Toxicity Criteria
时间窗: Up to 5 years
Patients will be rated for toxicity prior to each cycle using the NCI Common Toxicity Criteria (NCICTC; see the CTCAE, Version 4.0).
次要结局
- Kaplan-Meier Curves for Patient Overall Survival(Up to 5 years, survival)
- Time to Serum Ca-125 Nadir and/or CT Response (RECIST Criteria)(Up to 5 years (survival))